30845 Suppl Giot.pdf - Giornale Italiano di Ortopedia e Traumatologia

Durable Cure and reconstructive Success in Osteogenic Sarcoma
Fig. 2. Fig. 3.
clastic response may be a new effective treatment for osteogenic
sarcoma. Furthermore, these findings support the potential for
Fig. 4.
S16
development of an individualized approach to the selection and
administration of chemotherapeutic agents 12 .
Survival of young patients whose tumors are very sensitive
to chemotherapy exceeds 80%, and traditional reconstructive
methods have a limited durability. There is a pressing need to
improve prosthetic fixation. The newly developed Compress system
is a novel strategy that holds great promise. Our experience
includes 72 patients, including 62 with > 2 years of follow up
(2-10 years). Implant K-M survivorship is 89% at 5 years. This
is better than we found for cemented or uncemented implants 13 .
rEFErENCE
1 Marcove RC, Mike V, Hajek JV, et al. Osteogenic sarcoma under the age of
twenty-one. A review of one hundred and forty-five operative cases. J Bone
Joint Surg Am 1970;52:411-23.
2 Meyers PA, Heller G, Healey J, et al. Chemotherapy for nonmetastatic
osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin
Oncol 1992;10:5-15.
3 Rosen G, Marcove RC, Caparros B, et al. Primary osteogenic sarcoma:
the rationale for preoperative chemotherapy and delayed surgery. Cancer
1979;43:2163-77.
4 MacEwen EG, Kurzman ID, Rosenthal RC, et al. Therapy for osteosarcoma
in dogs with intravenous injection of liposome-encapsulated muramyl
tripeptide. J Natl Cancer Inst 1989;21:81:935-8.
5 Meyers PA, Schwartz CL, Krailo MD, et al. Osteosarcoma: the addition of
muramyl tripeptide to chemotherapy improves overall survival – a report
from the Children’s oncology group. J Clin Oncol 2008;26:633-8.
6 Lin PP, Pandey MK, Jin F, et al. Targeted mutation of p53 and Rb
in mesenchymal cells of the limb bud produces sarcomas in mice.
Carcinogenesis 2009;30:1789-95.
7 Ulaner GA, Huang HY, Otero J, et al. Absence of a telomere maintenance
mechanism as a favorable prognostic factor in patients with osteosarcoma.
Cancer Res 2003;63:1759-63.
8 Guo W, Gorlick R, Ladanyi M, et al. Expression of bone morphogenetic
proteins and receptors in sarcomas. Clin Orthop Relat Res
1999;(365):175-83.
9 Yang R, Hoang BH, Kubo T, et al. Over-expression of parathyroid hormone
type 1 receptor confers an aggressive phenotype in osteosarcoma. Int J
Cancer 2007;121:943-54.
10 Abdeen A, Chou AJ, Healey JH, et al. Correlation between clinical outcome
and growth factor pathway expression in osteogenic sarcoma. Cancer
2009;10.
11 Mintz MB, Sowers R, Brown KM, et al. An expression signature
classifies chemotherapy-resistant pediatric osteosarcoma. Cancer Res
2005;65:1748-54.
12 Gorlick R, Anderson P, Andrulis I, et al. Biology of childhood osteogenic
sarcoma and potential targets for therapeutic development: meeting
summary. Clin Cancer Res 2003 November 15;9:5442-53.
13 Farfalli GL, Boland PJ, Morris CD, et al. Early equivalence of uncemented
press-fit and compress(R) femoral fixation. Clin Orthop Relat Res.
2009;467:2792-9. [Epub ahead of print]